GF Fund Management CO. LTD. Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

GF Fund Management CO. LTD. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 83,069 shares of the medical device company's stock, valued at approximately $6,460,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after purchasing an additional 222,548 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of DexCom in the 4th quarter worth about $5,812,000. Merit Financial Group LLC bought a new position in DexCom in the fourth quarter worth about $228,000. Finally, Fifth Third Bancorp lifted its holdings in DexCom by 21.5% in the fourth quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company's stock worth $2,438,000 after buying an additional 5,553 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. The trade was a 8.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. This represents a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DXCM. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Canaccord Genuity Group upped their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.00.

DexCom Stock Performance

Shares of DXCM stock traded up $1.65 during mid-day trading on Wednesday, reaching $86.98. 2,859,842 shares of the company's stock traded hands, compared to its average volume of 4,367,029. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $128.63. The firm has a 50 day moving average price of $73.97 and a two-hundred day moving average price of $78.41. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $34.11 billion, a PE ratio of 60.83, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm earned $0.32 EPS. The company's revenue was up 12.5% on a year-over-year basis. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.